New research writes latest chapter in one drug's story
June 27, 2017
| by Susan Keown / Fred Hutch News Service
The leukemia drug gemtuzumab ozogamicin (Mylotarg) was pulled from the market seven years after initial approval. Now, new evidence may be bringing it back to life to treat a specific group of patients.
New Fred Hutch spinoff to commercialize cord blood stem cell therapies based on work by Drs. Colleen Delaney, Irwin Bernstein
Dec. 3, 2015
| By Susan Keown / Fred Hutch News Service
A new Fred Hutch spinoff, Nohla Therapeutics, will commercialize cord blood stem cell therapies based on work by Dr. Colleen Delaney and Dr. Irwin Bernstein. In preliminary studies, the company’s first product helps stem cells engraft more quickly after transplant and protects patients from deadly infections during this vulnerable period.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.